Evotec (EVO) Fundamental Analysis: Bull vs. Bear Case

EVO

Evotec

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

County of HQ

Germany

Next Earnings Date

11/05/25

Business Summary

The company operates as a drug development and specialty pharmaceutical platform, partnering with biotechnology and pharmaceutical firms to advance compounds through research, preclinical, and clinical stages. It generates revenue through collaborative research agreements, milestone payments, and development services, effectively monetizing scientific infrastructure rather than relying solely on blockbuster drug commercialization. Its moat lies in integrated discovery capabilities, scientific expertise, and long-term research partnerships that create switching costs for clients mid-development cycle. Cash flow durability depends on maintaining a steady pipeline of partnered programs and converting scientific output into recurring development revenue rather than binary drug approval wins.

VALUATION

P/E

-

Market Cap ($M USD)

$937

Forward P/E

65.8 PEG

-

PRICE TO SALES

1 PRICE TO BOOK

1 EV / EBITDA

27.8 5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0 5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$0.34

Next Year EPS Growth Estimate

$0.04

Next Year Revenue Growth Estimate

9.20%

Return on Equity (ROE)

-12.70%

FREE CASH FLOW

Operating Margin

-6.80%

Debt-to-Equity

0.6 Piotroski F-Score

6 Altman Z-Score

0.5 Return on Invested Capital (ROIC)

-7.10%

Current Ratio

2.1 Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Gainseekers Quantitative Analysis

Summary

This is not a growth story — it is a balance sheet survival story. A $937M market cap company with a Forward P/E of 65.8, negative operating margin of -12.70%, ROIC of -7.10%, and an Altman Z-Score of 0.5 is priced like a turnaround miracle despite flashing financial distress signals. The market is assigning a premium multiple to a business expected to post EPS of -$0.34 next year while currently generating subpar profitability. A Price/Sales of 1 and Price/Book of 1 suggest surface-level “cheapness,” but the combination of weak margins and a distress-level Z-score implies the equity carries material downside risk if execution falters. This is a fragile balance sheet wrapped in a speculative multiple.

AI Exposure / Tech Reliance

As a specialty and generic drug manufacturer, the company operates in a research-intensive, data-heavy ecosystem where AI-driven drug discovery and development optimization are increasingly critical. Firms in this space that integrate computational biology and predictive modeling can compress timelines and reduce R&D waste. However, capital constraints implied by financial weakness could limit aggressive AI investment relative to better-capitalized peers.

The Bull Case

A deep value or GARP investor could argue that a Price/Sales of 1 and Price/Book of 1 already discount substantial pessimism. The Piotroski F-Score of 6 signals that, operationally, the company is not in complete deterioration mode and retains some financial stability characteristics. Return on Equity of 9.20% shows that, despite negative operating margins, shareholder capital has generated positive accounting returns, suggesting potential restructuring leverage. With a Current Ratio of 2.1, short-term liquidity appears manageable, and if margins normalize from -12.70%, even modest operating leverage could significantly re-rate a $937M company trading at depressed sales multiples.

The Bear Case

The bear case is far more straightforward: an Altman Z-Score of 0.5 screams distress risk, and a Forward P/E of 65.8 is indefensible for a company with negative operating margins and negative forward EPS. ROIC at -7.10% confirms value destruction at the capital allocation level. Debt/Equity at -6.80% raises serious balance sheet quality concerns, suggesting structural financial complexity or erosion of equity base. With EPS expected to swing to -$0.34 and no dividend support, investors are effectively betting on a turnaround while absorbing material insolvency risk — that is speculation, not disciplined GARP.

Market Sentiment & Smart Money

Short Interest %

0.10%

Analyst Consensus

2.14 Average Analyst Price Target

$4.67

Institutional Ownership %

2.60%

1-Year Beta

1.09 Insider Buying % (6 Mo)

0.00%%

Distance to 52-Week High

54.80%

Distance to 52-Week Low

114.00%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.